Market Overview

UPDATE: Piper Jaffray Upgrades Osiris Therapeutics to Overweight on Strong Biosurgery Growth

Related OSIR
Osiris Announces a Strategic Partnership with Stryker for Marketing Osiris' Viable Bone Matrix
Merge Healthcare: Updated Research Report - Analyst Blog

Piper Jaffray upgraded Osiris Therapeutics (NASDAQ: OSIR) from Neutral to Overweight and maintained a $11.50 price target.

Piper Jaffray commented, "Osiris is blowing the doors off Biosurgery sales: up 284% yr/yr and 36% sequentially to $2.9 million in 4Q:12 and totaling $7.8 million for 2012. We now forecast Biosurgery sales growth of 123% to $17.5 million this year. Based on this robust growth, we are upgrading Osiris to Overweight and maintaining our $11.50 price target. Keep in mind that Osiris regained full rights to Prochymal from Genzyme/Sanofi and is now free to sign a new global licensing partnership."

Osiris Therapeutics closed at $6.91 on Tuesday.

Latest Ratings for OSIR

DateFirmActionFromTo
Sep 2014RF Lafferty & Co.Initiates Coverage onBuy
Oct 2013Piper JaffrayUpgradesNeutralOverweight
Aug 2013Piper JaffrayDowngradesOverweightNeutral

View More Analyst Ratings for OSIR
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Upgrades Analyst Ratings

 

Related Articles (OSIR)

Around the Web, We're Loving...

Get Benzinga's Newsletters